沙美特罗氟替卡松治疗支气管扩张伴气流受限患者的临床效果观察
|
摘要
目的观察沙美特罗氟替卡松治疗支气管扩张伴气流受限患者的临床效果。方法选取支气管扩张伴气流受限患者51例,随机分为治疗组26例和对照组25例。两组患者均采用常规治疗,治疗组在常规治疗基础上给予长期规律吸入沙美特罗氟替卡松。分别测定两组治疗前、治疗4个月后临床症状指标、肺功能、痰中中性粒细胞百分比,并进行比较分析。结果两组患者治疗前临床症状指标、肺功能、痰中中性粒细胞百分比各项指标比较差异均无统计学意义(P>0.05)。治疗组治疗后临床症状指标、肺功能指标较治疗前明显改善(P<0.05),痰中中性粒细胞百分比比治疗前明显降低(P<0.05);对照组各项指标改善不明显(P>0.05);两组治疗后比较差异有统计学意义(P<0.05)。结论沙美特罗氟替卡松治疗支气管扩张伴气流受限患者,可改善临床症状及肺功能,降低痰中中性粒细胞百分比。
Objective To observe the curative effect of salmeterol fluticasone on patients with bronchiectasis and limited airflow. Methods 51 patients with bronchiectasis and limited airflow were randomly divided into treatment group( n = 26) and control group( n = 25). The two groups were treated with conventional treatment and the treatment group inhaled additional long-term salmeterol fluticasone regularly. Their clinical symptoms,pulmonary functions and sputum neutrophil percentages were observed and measured before and 4 months after the treatment. Results The clinical symptoms,pulmonary functions and sputum neutrophil percentages had no significant differences between the two groups before the treatment( P > 0. 05). The clinical symptoms and the pulmonary function were improved significantly in the treatment group after the treatment,and the sputum neutrophil percentage was decreased obviously while there was no obvious change in the control group. Conclusion Salmeterol fluticasone can improve the clinical symptoms and lung function,reduce the sputum neutrophil percentage in patients with bronchiectasis and limited airflow.
Objective To observe the curative effect of salmeterol fluticasone on patients with bronchiectasis and limited airflow. Methods 51 patients with bronchiectasis and limited airflow were randomly divided into treatment group( n = 26) and control group( n = 25). The two groups were treated with conventional treatment and the treatment group inhaled additional long-term salmeterol fluticasone regularly. Their clinical symptoms,pulmonary functions and sputum neutrophil percentages were observed and measured before and 4 months after the treatment. Results The clinical symptoms,pulmonary functions and sputum neutrophil percentages had no significant differences between the two groups before the treatment( P > 0. 05). The clinical symptoms and the pulmonary function were improved significantly in the treatment group after the treatment,and the sputum neutrophil percentage was decreased obviously while there was no obvious change in the control group. Conclusion Salmeterol fluticasone can improve the clinical symptoms and lung function,reduce the sputum neutrophil percentage in patients with bronchiectasis and limited airflow.
引文
1陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社,2008:39-42.
2 李小玲,蔡绍曦,赵海金,等.噻托溴铵粉吸入剂对稳定期支气管扩张患者的临床疗效[J].南方医科大学学报,2010,30(5):1072-1074.
3 Ho C,Tipoe G,Zheng L,et al.In vitro study of regulation of IL-6production in bronchiectasis[J].Respir Med,2004,98(4):334-341.
4 尹世琦,桑玉兰.可必特与沐舒坦联合雾化吸入治疗慢性阻塞性肺疾病急性加重期患者的临床观察[J].中国临床新医学,2009,2(8):814-816.
5 丁会,王建国,孙晓艳,等.可逆性气流受限支气管扩张患者对支气管舒张药和糖皮质激素的反应性[J].吉林大学学报(医学版),2006,32(5):872-875.
6 许建钢,蒋萍.舒利迭对支气管扩张伴气流受限的临床疗效[J].山东医药,2011,51(28)89-90.
7 高蔚,翁婷.吸入激素对稳定期支气管扩张症患者痰中IL-6、IL-8、中性粒细胞表达的影响[J].临床肺科杂志,2008,13(9):1120-1121.
2 李小玲,蔡绍曦,赵海金,等.噻托溴铵粉吸入剂对稳定期支气管扩张患者的临床疗效[J].南方医科大学学报,2010,30(5):1072-1074.
3 Ho C,Tipoe G,Zheng L,et al.In vitro study of regulation of IL-6production in bronchiectasis[J].Respir Med,2004,98(4):334-341.
4 尹世琦,桑玉兰.可必特与沐舒坦联合雾化吸入治疗慢性阻塞性肺疾病急性加重期患者的临床观察[J].中国临床新医学,2009,2(8):814-816.
5 丁会,王建国,孙晓艳,等.可逆性气流受限支气管扩张患者对支气管舒张药和糖皮质激素的反应性[J].吉林大学学报(医学版),2006,32(5):872-875.
6 许建钢,蒋萍.舒利迭对支气管扩张伴气流受限的临床疗效[J].山东医药,2011,51(28)89-90.
7 高蔚,翁婷.吸入激素对稳定期支气管扩张症患者痰中IL-6、IL-8、中性粒细胞表达的影响[J].临床肺科杂志,2008,13(9):1120-1121.